Synthesis and Evaluation as NOP Ligands of Some Spiro[piperidine-4,2'(1'H)-quinazolin]-4'(3'H)-ones and Spiro[piperidine-4,5'(6'H)-[1,2,4]triazolo[1,5-c]quinazolines]
Novel hexahydrospiro[piperidine-4,1'-pyrrolo[3,4-c]pyrroles that act as potent and selective orphanin FQ/nociceptin (N/OFQ) receptor (NOP) agonists were identified. The best compound, (+)-5a, potently inhibited H-3-N/OFQ binding to the NOP receptor (K-i = 0.49 nM) but was > 1000-fold less potent in binding to MOP, KOP, and DOP opiate receptors. Further, (+)-5a potently stimulated GTPgammaS binding to NOP membranes (EC50 = 65 nM) and inhibited forskolin-mediated cAMP accumulation in NOP-expressing cells (EC50 = 9.1 nM) with a potency comparable to that of the natural peptide agonist N/OFQ. These results indicate that (+)-5a is a highly selective and potent small-molecule full agonist of the NOP receptor.
THIENOPYRIMIDINONE DERIVATIVES AS mGluR1 ANTAGONISTS
申请人:KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
公开号:US20140228565A1
公开(公告)日:2014-08-14
Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Also disclosed are methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.
subtype 1 (mGluR1) is a potential target for the treatment of neuropathic pain, and there has been much effort to discover mGluR1antagonists. In this study, a series of N 3‐alkyl‐thienopyrimidin‐4‐ones were prepared by introducing various alkyl and aryl groups to the N 3‐ and 7‐positions of the thienopyrimidin‐4‐one core structure, respectively, and their inhibitory activities against mGluR1 were biologically
Versatile routes for synthesis of diarylamines through acceptorless dehydrogenative aromatization catalysis over supported gold–palladium bimetallic nanoparticles
palladium nanoparticle catalyst (Pd/TiO2) gave the desired diarylamines, the catalyticactivity was inferior to that of Au–Pd/TiO2. Moreover, the activity of Au–Pd/TiO2 was superior to that of a physical mixture of Au/TiO2 and Pd/TiO2. The present Au–Pd/TiO2-catalyzed transformation of cyclohexylamines proceeds through complex pathways comprising amine dehydrogenation, imine disproportionation, and condensation
[EN] ANTIMICROBIAL COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ANTIMICROBIENS ET PROCÉDÉS
申请人:CURZA GLOBAL LLC
公开号:WO2021097061A1
公开(公告)日:2021-05-20
The application is directed to compounds that are active as antibacterial agents. The compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes for making the compounds.
The present invention relates to compounds according to formula 1,
which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.